灯盏花素注射液治疗病毒性肝炎高胆红素血症的疗效

Effects of Breviscapine Injection on hyperbilirubinemia caused by viral hepatitis

目的观察灯盏花素注射液治疗病毒性肝炎高胆红素血症的临床疗效。方法将79例病毒性肝炎高胆红素血症患者随机分成对照组和治疗组,两组均采用相同的基础治疗方法,治疗组加用灯盏花素注射液静滴,观察两组治疗前后甲襞微循环及肝功能(TBil、ALT、AST)的变化。结果两组患者治疗后甲襞微循环加权积分、血清总胆红素(TBil)及丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)均有显著下降;治疗组中甲襞微循环加权积分及TBil、ALT、AST下降较对照组更明显,总有效率治疗组92.50%,对照组为74.36%,两组相比差异有统计学意义(P<0.05,χ2=8.775);治疗组在改善血液微循环、降酶、退黄方面优于对照组,差异有显著统计学意义(P<0.01)。结论灯盏花素注射液治疗病毒性肝炎高胆红素血症具有良好的临床疗效,适合各基层医院推广应用。

Objective To observe the clinical therapeutic efficacy of Breviscapine Injection on hyperbilirubinemia caused by viral hepatitis. Methods Seventy nine patients with hyperbilirubinemia caused by viral hepatitis were randomly divided into two groups, who both received the same conventional therapy. In addition to the conventional therapy, 40 cases in treatment group were treated with Breviscapine Injection （40 mg） , given by intraveous drip, once per day. Indexes such as the total efficacy, the nail fold microcirculation and live function （TBil, ALT, AST） were observed. Results Compared to the control group, the treatment group demonstrates a significantly low weighting calculus value in nail fold microcirculation as well as low content of TBil, ALT, AST. The total effective rate in the treatment group and the control group were 92.50% and 74.36%, respectively, which was significantly different （P 〈0.05, χ2 = 8. 775）. The treatment group was significantly superior to the control group in reducing mend blood-microcirculation, ALT and TBil （P 〈 0.01 ）. Conclusions Breviscapine Injection may be effective on hyperbilirubinemia caused by viral hepatitis and the regimen can be applied in all hospitals with basic level.